Glaukos (GKOS) reported $143.12 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 35.7%. EPS of -$0.28 for the same period compares to -$0.40 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $142.93 million, representing a surprise of +0.13%. The company delivered an EPS surprise of -26.47%, with the consensus EPS estimate being -$0.22.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Glaukos performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues by product category- International- Glaucoma: $32.78 million versus $31.67 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +17.6% change.
- Revenues by product category- United States- Glaucoma: $86.4 million compared to the $81.11 million average estimate based on six analysts. The reported number represents a change of +53.5% year over year.
- Net Sales- Corneal Health: $24 million versus the six-analyst average estimate of $21.06 million. The reported number represents a year-over-year change of +12.4%.
- Net Sales- Glaucoma: $119.2 million versus the six-analyst average estimate of $112.79 million. The reported number represents a year-over-year change of +41.7%.
View all Key Company Metrics for Glaukos here>>>
Shares of Glaukos have returned -9% over the past month versus the Zacks S&P 500 composite's -1.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Glaukos Corporation (GKOS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
